BNP
[BNP]
EPTIS factsheet 142554 | Last revision 2024-09-24 | URL: https://www.eptis.bam.de/pts142554 https://www.eptis.bam.de/pts142554
| PT provider | |||||||||||||
| PT provider | Weqas Weqas | ||||||||||||
| Based in | United Kingdom | ||||||||||||
| Language(s) | |||||||||||||
| Remarks | Natriuretic peptide testing – B-type natriuretic peptide (BNP) or N-terminal pro-B-type natriuretic peptide (NT-proBNP) is an important tool for rapidly assessing adults presenting with new suspected acute heart failure. Participants can enrol in the programme most appropriate to their testing method and analyte i.e. laboratory methods for BNP, NT-proBNP or point of care testing (PoCT). Separate samples are provided for BNP and NT-proBNP. PoCT devices are assessed separately to laboratory methods. Three samples covering the appropriate physiological and pathological range including challenging samples near the diagnostic thresholds are distributed bimonthly. The base material for BNP is human EDTA plasma and for NT-proBNP lithium heparin plasma to reflect the preferred sample type used for patient testing. The samples consist of a panel of linearly related samples produced from donations from healthy volunteers spiked with natriuretic peptides. Recombinant human BNP-32 and NT-proBNP respectively are added, with the addition of protease inhibitors to improve stability. For BNP the samples are dispatched by Courier on dry ice, however, multiple distributions can be dispatched in one shipment to minimise costs. Key Features: - Surrogate, clinically appropriate samples at diagnostic thresholds. - Suitable for both Laboratory and PoCT analysers. - Preferred sample type – EDTA plasma or Lithium Heparin plasma. - Linearly related panel covering a clinically relevant range. - Liquid human serum samples require no pre-analytical preparation. For more information: https://www.weqas.com/services/eqa/bnp/ or contact@weqas.com | ||||||||||||
| Keywords | |||||||||||||
| Product groups |
Health care / medical devices
|
||||||||||||
| Testing fields |
Medical analysis
|
||||||||||||
| Technical details | |||||||||||||
|
|||||||||||||
| Aims of the PT scheme | |||||||||||||
| Target group of participants | Suitable for both Laboratory and POCT analysers. | ||||||||||||
| Linked to specific legislation / standards | Accreditation by UKAS based on ISO/IEC 17043. | ||||||||||||
| Additional, subsidiary aims | validation of testing methods | ||||||||||||
| Number of participants | |||||||||||||
| Accredited or otherwise reviewed by a 3rd party |
Accredited by UKAS on the basis of ISO/IEC 17043 |
||||||||||||
| Operation is commissioned / requested by | |||||||||||||
| Fees and frequency | |||||||||||||
| Participation fee | https://www.weqas.com/participantzone/subscription-charges/ | ||||||||||||
| Regularly operated | Yes (Frequency: Bimonthly. Samples: 3 x 0.5mL.) | ||||||||||||
| Year of first operation | 2005 | ||||||||||||
| Contact details of the PT provider | |||||||||||||
| Provider | Contact person | ||||||||||||
|
Weqas
Unit 6, Parc Ty Glas CF14 5DU Cardiff United Kingdom Phone: 44 (0) 2920 314750 Fax: Web: http://www.weqas.com http://www.weqas.com |
Laura Lloyd-Lewis
Phone: 44 (0) 29218 32884 Fax: Email: laura.lloyd-lewis@wales.nhs.uk laura.lloyd-lewis@wales.nhs.uk |
||||||||||||
If you find any mistakes please contact the responsible EPTIS coordinator in United Kingdom,
Mr Savvas Xystouris.
Mr Savvas Xystouris.